EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FYCO1 Peptide Analogs: Design and Characterization of Autophagy Inhibitors as Co-Adjuvants in Taxane Chemotherapy of Prostate Cancer

Enrico Mario Alessandro Fassi iD, Roberta Manuela Moretti iD, Marina Montagnani Marelli iD, Mariangela Garofalo, Alessandro Gori iD, Cristiano Pesce iD, Marco Albani iD, Erica Ginevra Milano, Jacopo Sgrignani iD, Andrea Cavalli, Giovanni Grazioso iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26115365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Enrico Mario Alessandro Fassi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via L. Mangiagalli 25, 20133 Milano, Italy. Hauptthemen laut MEDLINE: Autophagy, Prostatic Neoplasms, Peptides, Microtubule-Associated Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Center for Gene Therapy and Drugs Based on RNA Technology, Ministero dell'università e della ricerca, National Center for Gene Therapy and Drugs Based on RNA Technology—MUR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autophagy plays a central role in cellular degradation and recycling pathways involving the formation of autophagosomes from cellular components. The Atg8 protein family, particularly LC3, is essential to this process, and dysregulation has been implicated in many diseases (including cancer). Furthermore, therapeutic strategies targeting Atg8 proteins like LC3 can be advanced by exploiting the expanding knowledge of the “LC3 interacting region” (LIR) domain to develop inhibitory ligands. Here, we report a computational approach to design novel peptides that inhibit LC3B. The LIR domain of a known LC3B binder (the FYCO1 peptide) was used as a starting point to design new peptides with unnatural amino acids and conformational restraints. Accomplishing molecular dynamics simulations and binding free energy calculations on the complex of peptide–LC3B, new promising FYCO1 analogs were selected. These peptides were synthesized and investigated by biophysical and biological experiments. Their ability to affect cellular viability was determined in different cancer cell lines (prostate cancer, breast cancer, lung cancer, and melanoma). In addition, the ability to inhibit autophagy and enhance the apoptotic activity of Docetaxel was evaluated in PC-3 prostate cancer cells. In conclusion, this research presents a rational approach to designing and developing LC3B inhibitors based on the FYCO1-LIR domain. The designed peptides hold promise as potential therapeutic agents for cancer and as tools for further elucidating the role of LC3B in autophagy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutophagyProstatic NeoplasmsPeptidesMicrotubule-Associated ProteinsTaxoidsAntineoplastic AgentsHumansMaleCell Line, TumorMolecular Dynamics SimulationApoptosisDrug DesignCell SurvivalDocetaxelBridged-Ring Compounds

Stichwörter der Autor:innen

Atg8FYCO1LC3B bindersLIR motifautophagycancerpeptide

Substanzen

PeptidesMicrotubule-Associated ProteinsTaxoidsAntineoplastic AgentsMAP1LC3B protein, humantaxaneDocetaxelBridged-Ring Compounds

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via L. Mangiagalli 25, 20133 Milano, Italy.
  • Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via G. Balzaretti 9, 20133 Milano, Italy.
  • Department of Pharmaceutical and Pharmacological Sciences, Università di Padova, Via F. Marzolo 5, 35131 Padova, Italy.
  • National Research Council of Italy, Istituto di Scienze e Tecnologie Chimiche (SCITEC-CNR), Via M. Bianco 9, 20131 Milano, Italy.
  • Institute for Research in Biomedicine (IRB), Via Chiesa 5, 6500 Bellinzona, Switzerland.

ORCID-Profile: Enrico Mario Alessandro Fassi, Roberta Manuela Moretti, Marina Montagnani Marelli, Alessandro Gori, Cristiano Pesce, Marco Albani, Jacopo Sgrignani, Giovanni Grazioso

Förderung

  • National Center for Gene Therapy and Drugs Based on RNA Technology
  • Ministero dell'università e della ricerca
  • National Center for Gene Therapy and Drugs Based on RNA Technology—MUR
  • NextGeneration EU program

Zitieren

APA

Fassi, E. M. A., Moretti, R. M., Montagnani Marelli, M., Garofalo, M., Gori, A., Pesce, C., Albani, M., Milano, E. G., Sgrignani, J., Cavalli, A., & Grazioso, G. (2025). FYCO1 Peptide Analogs: Design and Characterization of Autophagy Inhibitors as Co-Adjuvants in Taxane Chemotherapy of Prostate Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115365

Vancouver

Fassi EMA, Moretti RM, Montagnani Marelli M, Garofalo M, Gori A, Pesce C, et al. FYCO1 Peptide Analogs: Design and Characterization of Autophagy Inhibitors as Co-Adjuvants in Taxane Chemotherapy of Prostate Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115365

BibTeX
@article{Fassi2025,
  author = {Fassi, Enrico Mario Alessandro and Moretti, Roberta Manuela and Montagnani Marelli, Marina and Garofalo, Mariangela and Gori, Alessandro and Pesce, Cristiano and Albani, Marco and Milano, Erica Ginevra and Sgrignani, Jacopo and Cavalli, Andrea and Grazioso, Giovanni},
  title = {FYCO1 Peptide Analogs: Design and Characterization of Autophagy Inhibitors as Co-Adjuvants in Taxane Chemotherapy of Prostate Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26115365}
}
Kostenlos starten →